Midostaurin: an emerging treatment for acute myeloid leukemia patients

Midostaurin: an emerging treatment for acute myeloid leukemia patients

Item
http://www.wikidata.org/entity/Q26749271
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.Precision therapy for acute myeloid leukemia.Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.Expression and clinical significance of serum MMP-7 and PTEN levels in patients with acute myeloid leukemia.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AMLIncubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia
P2860

Midostaurin: an emerging treatment for acute myeloid leukemia patients

Item
http://www.wikidata.org/entity/Q26749271
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@ast
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@en
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@nl
type
label
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@ast
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@en
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@nl
prefLabel
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@ast
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@en
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P478
P50
P577
P698
P921
P932
P3181
P356
P1433
P1476
Midostaurin: an emerging treatment for acute myeloid leukemia patients
@en
P2093
P2860
P304
P31
P3181
P356
P407
P478
P50
P577
P698
P921
P932